{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:39:17Z","timestamp":1770493157839,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To study the treatment patterns, visual outcomes and safety profile of intravitreal dexamethasone implant (IDI) used for the treatment of macular edema secondary to retinal vein occlusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Up to 2 years of routinely collected anonymized data within electronic medical record systems were remotely extracted from 16 centers. The outcome measures include visual outcome, number of injections, and safety measures, including the rate of intraocular pressure (IOP) rise, frequency of IOP-lowering medication usage, and cataract surgery rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The study included 688 eyes (44.4%) with central retinal vein occlusion and 862 eyes (55.6%) with branch retinal vein occlusion; 1,250 eyes (80.6%) were treatment naive and 28% (275\/989) had high IOP or were on IOP-lowering medications before IDI use. It was found that 31% (476) of eyes received two injections, and 11.7% (182) and 3.7% (58) of eyes received three and four injections, respectively. The mean baseline Snellen visual acuity improved from 20\/125 to 20\/40 after the first injection. The probability of cataract surgery was 15% at 24 months. The proportion of eyes with \u226510 mmHg change from baseline was higher in phakic (14.2%) compared with pseudophakic eyes (5.4%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004). Three eyes required IOP filtering surgery (0.2%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The visual results of IDI in eyes with macular edema secondary to retinal vein occlusion in the real world are comparable to those of clinical trial setting. Increased IOP in eyes with preexisting ocular hypertension or glaucoma can be controlled with additional medical treatment. Intraocular pressure rise with IDI may be more frequent in phakic than in pseudophakic eyes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003698","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:55:03Z","timestamp":1675360503000},"page":"679-687","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-8925","authenticated-orcid":false,"given":"Mohamed Kamel","family":"Soliman","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, Egypt;"},{"name":"Department of Ophthalmology and Visual Sciences, University Hospitals Eye Institute, Case Western Reserve University, Cleveland, Ohio;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[{"name":"Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Belfast Health and Social Care Trust, Belfast, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Brand","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Menon","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Cilliers","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, South Warwickshire NHS Foundation Trust, Warwick, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Natha","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Appley Bridge, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Ross","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University of Bristol and Bristol Eye Hospital, Bristol, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Sarhan","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aires","family":"Lobo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Bedford Hospital NHS Trust, Bedford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Chong","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Oxford University Hospitals NHS Trust, Oxford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niaz","family":"Islam","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toks","family":"Akerele","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Hinchingbrooke Health Care NHS Trust, Huntingdon, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Shakarchi","sequence":"additional","affiliation":[{"name":"Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sallam","sequence":"additional","affiliation":[{"name":"Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and"},{"name":"Gloucestershire Eye Unit, Cheltenham General Hospital, Cheltenham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the United Kingdom Ozurdex in Retinal Vein Occlusion Electronic Medical Records (UK Ozurdex RVO EMR) Users Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R3-20250605","article-title":"Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion","year":"2011"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (ozurdex): the safodex study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000452896","article-title":"Long-term real-life efficacy and safety of repeated Ozurdex\u00ae injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study","volume":"236","author":"Pommier","year":"2016","journal-title":"Ophthalmologica"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/IAE.0b013e318297f842","article-title":"Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study)","volume":"34","author":"Capone","year":"2014","journal-title":"Retina"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ophtha.2020.03.020","article-title":"Long-term visual outcomes after release from protocol in patients who participated in the inhibition of VEGF in age-related choroidal neovascularisation (IVAN) trial","volume":"127","author":"Evans","year":"2020","journal-title":"Ophthalmology"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \"hand motion\" and \"counting fingers\" using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2016.07.037","article-title":"UK age-related macular degeneration electronic medical record system (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients","volume":"123","author":"Johnston","year":"2016","journal-title":"Ophthalmology"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.eye.6703031","article-title":"The cataract national dataset electronic multi-centre audit of 55,567 operations: anaesthetic techniques and complications","volume":"23","author":"El-Hindy","year":"2009","journal-title":"Eye (Lond)"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/IAE.0000000000000523","article-title":"The royal college of ophthalmologists' national ophthalmology database study of vitreoretinal surgery: report 4, epiretinal membrane","volume":"35","author":"Jackson","year":"2015","journal-title":"Retina"},{"key":"R12-20250605","first-page":"1255","article-title":"Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study","volume":"9","author":"Albiani","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00417-016-3431-x","article-title":"Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial","volume":"255","author":"Eter","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"e0209997","DOI":"10.1371\/journal.pone.0209997","article-title":"Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world","volume":"14","author":"Zarranz-Ventura","year":"2019","journal-title":"PLoS One"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","article-title":"Safety of 6000 intravitreal dexamethasone implants","volume":"104","author":"Rajesh","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1111\/aos.12190","article-title":"Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice","volume":"91","author":"Matonti","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00417-016-3553-1","article-title":"Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension","volume":"255","author":"Theodoropoulou","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000438759","article-title":"Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex\u00ae) on intraocular pressure in patients with macular edema","volume":"54","author":"Mazzarella","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3341\/kjo.2019.0142","article-title":"Comparison of anatomical and functional outcomes of intravitreal dexamethasone implant between phakic and pseudophakic eyes with diabetic macular edema","volume":"34","author":"Kald\u0131r\u0131m","year":"2020","journal-title":"Korean J Ophthalmol"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.eye.6701895","article-title":"Corticosteroid-induced glaucoma: a review of the literature","volume":"20","author":"Kersey","year":"2006","journal-title":"Eye (Lond)"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1755-3768.2009.01656.x","article-title":"Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection?","volume":"89","author":"Kerimoglu","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.preteyeres.2010.04.003","article-title":"Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","volume":"96","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study","volume":"169","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/bjophthalmol-2020-317306","article-title":"Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections","volume":"105","author":"Gale","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.4103\/ijo.IJO_382_19","article-title":"Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: a systematic review and meta-analysis of randomized controlled trials","volume":"67","author":"He","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1120672120947595","article-title":"Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: systematic review and meta-analysis","volume":"31","author":"Pranata","year":"2021","journal-title":"Eur J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:07:59Z","timestamp":1749143279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003698","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}